Aerosol interferon for RSV pneumonia in toddlers
Treatments studied
Part of Infections, Lungs & breathing clinical trials.
This study tests an inhaled form of peginterferon alpha-2b for children aged 1 to 3 years who have pneumonia caused by RSV. The goal is to see if this treatment helps them recover faster.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be between 1 and 3 years old.
- They must have tested positive for RSV and have symptoms like fever, cough, and wheezing.
- Symptoms must have started within the last 72 hours.
- Your child must not have severe breathing problems or other serious complications.
- They must not have used certain antiviral drugs or immunoglobulin in the past 30 days.
- A parent or legal guardian must sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new injection (SIBP-A16) designed to protect infants against RSV, a common virus that can cause serious lung infections in babies. The trial will see if the injection is safe and works in both premature and full-term infants during their first RSV season.
This trial tests an experimental vaccine against respiratory syncytial virus (RSV) in children who are at high risk of serious RSV illness due to chronic medical conditions or weakened immune systems. The goal is to see if the vaccine is safe and effective in preventing RSV-related lower respiratory tract infections.
This study tests an inhaled medication for adults with a respiratory syncytial virus (RSV) infection that causes symptoms like cough or trouble breathing. If you have RSV and these symptoms, this treatment might help you feel better.
This trial tests if remdesivir (Veklury) is safe and helps clear RSV in babies and toddlers who are hospitalized. It may help your child recover faster from severe RSV symptoms.
This trial tests a new medicine called Zelicapavir for babies and young children (28 days to 3 years old) who have respiratory syncytial virus (RSV) infection. The medicine aims to help them recover faster and with fewer complications.
This study tests a new vaccine designed to protect against respiratory syncytial virus (RSV), a common virus that can cause serious lung infections. The vaccine is given as a shot, and the study will check how your immune system responds to it.
Hear when a new Respiratory Syncytial Virus (RSV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.